Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

Gang Li; Ryan L Woltz; Cheng-Yu Wang; Lu Ren; Pei-Xin He; Shan-Dong Yu; Xue-Qin Liu; Vladimir Yarov-Yarovoy; Dan Hu; Nipavan Chiamvimonvat; Lin Wu

doi:10.3389/fphar.2020.01182

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

Front Pharmacol. 2020 Aug 4:11:1182. doi: 10.3389/fphar.2020.01182. eCollection 2020.

Authors

Gang Li¹, Ryan L Woltz², Cheng-Yu Wang¹, Lu Ren², Pei-Xin He¹, Shan-Dong Yu¹, Xue-Qin Liu³, Vladimir Yarov-Yarovoy⁴, Dan Hu⁵, Nipavan Chiamvimonvat^{2

6}, Lin Wu^{1

7}

Affiliations

¹ Department of Cardiology, Peking University First Hospital, Beijing, China.
² Division of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Davis, CA, United States.
³ Department of Pediatrics, Peking University First Hospital, Beijing, China.
⁴ Department of Physiology and Membrane Biology, School of Medicine, University of California, Davis, Davis, CA, United States.
⁵ Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University and Hubei Key Laboratory of Cardiology, Wuhan, China.
⁶ Department of Veterans Affairs, Northern California Health Care System, Mather, CA, United States.
⁷ Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China.

Abstract

Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late I _Na) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX) -sensitive (N1325S and R1623Q) and -insensitive (M1652R) mutations remains to be elucidated.

Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX.

Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias, and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5-13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late I _Na with the greatest amplitude in the M1652R channel (n = 9-15, P < 0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late I _Na in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Na_v1.5 to MEX through allosteric mechanisms by changing the conformation of Na_v1.5 to become more or less favorable for MEX binding. Late I _Na inhibitors suppressed late I _Na in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n = 4-7, P < 0.05).

Conclusion: The N1325S, R1623Q, and M1652R mutations are associated with a variable augmentation of late I _Na, which was reversed by MEX. M1652R mutation changes the conformation of Na_v1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling, and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late I _Na inhibitors.

Keywords: LQT3; gene mutation; late sodium current; mexiletine; torsades de pointes.